From Medscape Rheumatology

Coverage From The

European League Against Rheumatism (EULAR) 2019 Congress

June 12 - 15, 2019; Madrid, Spain

June 12 - 15, 2019 Madrid, Spain
  • New JAK Inhibitor Hits Rheumatoid Arthritis Targets Filgotinib is effective and well tolerated by patients with moderate to severe rheumatoid arthritis, early phase 3 results show, and investigators speculate it will enter the market in about 2 years.

Conference News

Popular News From EULAR 2018

  • NSAIDs Increase Cardiovascular Risk in Osteoarthritis NSAIDs Increase Cardiovascular Risk in Osteoarthritis Nonsteroidal anti-inflammatory drugs contribute to the elevated risk for cardiovascular disease in people with osteoarthritis, new research shows, but alternatives for pain management are limited.
  • Canakinumab Halves Gout in Patients With Atherosclerosis Canakinumab Halves Gout in Patients With Atherosclerosis However, the interleukin-1 inhibitor has no effect on serum urate, which is a risk marker for both gout and cardiovascular disease, a new analysis of data from CANTOS shows.
  • Ankylosing Spondylitis Patients at Risk for Self-Harm Ankylosing Spondylitis Patients at Risk for Self-Harm People with this painful condition that affects the spine are at higher risk of harming themselves, a large study confirms; however, the mental health effects of the disease are often ignored.

Medscape Rheumatology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage